Haisco Pharmaceutical - Public Comps and Valuation Multiples

Haisco Pharmaceutical Overview

About Haisco Pharmaceutical

Haisco Pharmaceutical Group Co Ltd is a pharmaceutical company based in China. It is mainly engaged in the research, development, manufacture, and sale of drugs for liver disease. Its product portfolio includes parenteral nutrition drugs, antibiotics, anesthetic agents, digestive system drugs and tumour adjuvant drug series. The company's products are being used in first rank hospitals in China.

Founded

2000

HQ

Employees

n/a

Website

haisco.com

Sectors

Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $640M

LTM EBITDA $111M

EV

$8.7B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Haisco Pharmaceutical Financials

As of December 2025, Haisco Pharmaceutical reported last 12-month revenue of $640M and EBITDA of $111M.

In the same period, Haisco Pharmaceutical generated $472M in LTM gross profit and $67.3M in net income.

See Haisco Pharmaceutical valuation multiples based on analyst estimates

Haisco Pharmaceutical P&L

In the most recent fiscal year, Haisco Pharmaceutical reported revenue of $532M and EBITDA of $107M.

Haisco Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Haisco Pharmaceutical valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$640M	XXX	$532M	XXX	XXX	XXX
Gross Profit	$472M	XXX	$380M	XXX	XXX	XXX
Gross Margin	74%	XXX	71%	XXX	XXX	XXX
EBITDA	$111M	XXX	$107M	XXX	XXX	XXX
EBITDA Margin	17%	XXX	20%	XXX	XXX	XXX
EBIT	$75.3M	XXX	$65.6M	XXX	XXX	XXX
EBIT Margin	12%	XXX	12%	XXX	XXX	XXX
Net Profit	$67.3M	XXX	$56.5M	XXX	XXX	XXX
Net Margin	11%	XXX	11%	XXX	XXX	XXX
Net Debt	XXX	XXX	$15.9M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Haisco Pharmaceutical including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $640M. EBITDA for the last twelve months was $111M. In the most recent fiscal year, Haisco Pharmaceutical achieved $532M in revenue and $107M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$640M	Analyst estimates available to subscribers	$532M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$472M	Analyst estimates available to subscribers	$380M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	73.8% gross margin	Analyst estimates available to subscribers	71.5% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$111M	Analyst estimates available to subscribers	$107M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	17.3% EBITDA margin	Analyst estimates available to subscribers	20.2% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$75.3M	Analyst estimates available to subscribers	$65.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	11.8% EBIT margin	Analyst estimates available to subscribers	12.3% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$67.3M	Analyst estimates available to subscribers	$56.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	10.5% net profit margin	Analyst estimates available to subscribers	10.6% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$15.9M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Haisco Pharmaceutical

This financial data table provides comprehensive performance metrics for Haisco Pharmaceutical, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Haisco Pharmaceutical generated $640M in revenue over the last twelve months.
The company achieved $111M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $472M.
Net income over the last twelve months reached $67.3M.

Fiscal Year Performance

In the most recent fiscal year, Haisco Pharmaceutical reported $532M in total revenue.
Fiscal year EBITDA was $107M.
The company maintained a gross profit margin of 71.5% in the most recent fiscal year.
EBITDA margin for the fiscal year was 20.2%.
Net profit margin reached 10.6% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Haisco Pharmaceutical. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Haisco Pharmaceutical Stock Performance

Haisco Pharmaceutical has current market cap of CNY 60.3B (or $8.6B), and EV of CNY 61.2B (or $8.7B).

Market Cap Evolution

Haisco Pharmaceutical Stock Data

As of January 16, 2026, Haisco Pharmaceutical's stock price is CNY 54 (or $8).

See Haisco Pharmaceutical trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$8.7B	$8.6B	XXX	XXX	XXX	XXX	$0.06

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Haisco Pharmaceutical Valuation Multiples

Haisco Pharmaceutical's trades at 13.7x EV/Revenue multiple, and 79.0x EV/EBITDA.

See valuation multiples for Haisco Pharmaceutical and 15K+ public comps

Haisco Pharmaceutical Financial Valuation Multiples

As of January 16, 2026, Haisco Pharmaceutical has market cap of $8.6B and EV of $8.7B.

Equity research analysts estimate Haisco Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Haisco Pharmaceutical has a P/E ratio of 128.0x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$8.6B	XXX	$8.6B	XXX	XXX	XXX
EV (current)	$8.7B	XXX	$8.7B	XXX	XXX	XXX
EV/Revenue	13.7x	XXX	13.7x	XXX	XXX	XXX
EV/EBITDA	79.0x	XXX	79.0x	XXX	XXX	XXX
EV/EBIT	116.1x	XXX	116.1x	XXX	XXX	XXX
EV/Gross Profit	18.5x	XXX	n/a	XXX	XXX	XXX
P/E	128.0x	XXX	128.0x	XXX	XXX	XXX
EV/FCF	n/a	XXX	43986.2x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Haisco Pharmaceutical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Haisco Pharmaceutical Margins & Growth Rates

Haisco Pharmaceutical's last 12 month revenue growth is 25%

Haisco Pharmaceutical's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Haisco Pharmaceutical's rule of 40 is 41% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Haisco Pharmaceutical's rule of X is 79% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Haisco Pharmaceutical and other 15K+ public comps

Haisco Pharmaceutical Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	25%	XXX	24%	XXX	XXX	XXX
EBITDA Margin	17%	XXX	17%	XXX	XXX	XXX
EBITDA Growth	34%	XXX	17%	XXX	XXX	XXX
Rule of 40	41%	XXX	42%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	79%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	3%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	17%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	59%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial